Valion Bio (VBIO) Total Current Liabilities (2021 - 2026)
Valion Bio (VBIO) posted quarterly Total Current Liabilities of $646000.0 for Q4 2025, up 137.5% year-over-year from $272000.0 in Q4 2024, and up 1.25% quarter-over-quarter from $638000.0 in Q3 2025.
Valion Bio (VBIO) Total Current Liabilities (2021 - 2026) Analysis & Trends
Valion Bio's Total Current Liabilities history runs 5 years deep, the most recent figure standing at $646000.0 for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 137.5% year-over-year to $646000.0; the TTM figure through Dec 2025 stood at $646000.0 (up 137.5% YoY), while the FY2025 annual figure was $646000.0, up 137.5% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $646000.0, up from $638000.0 in the prior quarter.
- The five-year high for Total Current Liabilities was $2.4 million in Q2 2022, with the low at $272000.0 in Q4 2024.
- The 5-year median for Total Current Liabilities is $1.0 million (2023), against an average of $1.1 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities slumped 80.59% in 2024, then soared 137.5% in 2025.
- Valion Bio's Total Current Liabilities stood at $1.2 million in 2021, then jumped by 54.06% to $1.9 million in 2022, then declined by 25.4% to $1.4 million in 2023, then plunged by 80.59% to $272000.0 in 2024, then jumped by 137.5% to $646000.0 in 2025.
- Business Quant data shows VBIO's Total Current Liabilities at $646000.0 in Q4 2025, $638000.0 in Q3 2025, and $821000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 630.93 Mn |
| 10 | Valion Bio | 423,175.64 | -1.78 Mn | -45,000.00 | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.05 Mn |
| Dec 31, 2025 | 646,000.00 |
| Sep 30, 2025 | 638,000.00 |
| Jun 30, 2025 | 821,000.00 |
| Mar 31, 2025 | 741,000.00 |
| Dec 31, 2024 | 272,000.00 |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Mar 31, 2024 | 992,000.00 |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | 2.02 Mn |
| Jun 30, 2022 | 2.38 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.22 Mn |